Athira Pharma, Inc. — Director's Dealing 2023

May 22, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2023-05-19

Reporting Person: FLUKE JOHN M JR (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-19	Stock Option (Right to Buy)	$2.89	A	20900	Acquired	2033-05-18	Common Stock (20900)	Direct

Footnotes

F1: The shares subject to the option will vest on the earlier of (i) May 19, 2024, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 19, 2023. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.